Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Sell
44
AVNS Quote, Financials, Valuation and Earnings
Last price:
$12.10
Seasonality move
:
-1.26%
Day range:
$12.06 - $12.29
52-week range:
$11.84 - $25.36
Dividend yield:
0%
P/E ratio:
45.94x
P/S ratio:
0.82x
P/B ratio:
0.67x
Volume:
282.5K
Avg. volume:
448.6K
1-year change:
-38.3%
Market cap:
$559.6M
Revenue:
$687.8M
EPS (TTM):
-$8.37
Analysts' Opinion
-
Consensus RatingAvanos Medical has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.00, Avanos Medical has an estimated upside of 15.7% from its current price of $12.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $12.10.
Fair Value
-
According to the consensus of 1 analyst, Avanos Medical has 15.7% upside to fair value with a price target of $14.00 per share.
AVNS vs. S&P 500
-
Over the past 5 trading days, Avanos Medical has underperformed the S&P 500 by -2.51% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Avanos Medical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avanos Medical has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Avanos Medical reported revenues of $167.5M.
Earnings Growth
-
Avanos Medical earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Avanos Medical reported earnings per share of $0.14.
Enterprise value:
570M
EV / Invested capital:
--
Price / LTM sales:
0.82x
EV / EBIT:
20.38x
EV / Revenue:
0.83x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
5.00x
Price / Operating cash flow:
4.93x
Enterprise value / EBITDA:
9.34x
Gross Profit (TTM):
$376.3M
Return On Assets:
-26.57%
Net Income Margin (TTM):
-55.8%
Return On Equity:
-35.96%
Return On Invested Capital:
-31.51%
Operating Margin:
6.15%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $684.1M | $680.1M | $689.2M | $166.1M | $167.5M | |
| Gross Profit | $396.1M | $383.1M | $376.3M | $94.8M | $89.8M | |
| Operating Income | $33.4M | $14.3M | $46.8M | $4M | $10.3M | |
| EBITDA | $83.8M | $62.7M | -$340.2M | $16M | $21.4M | |
| Diluted EPS | $0.94 | -$1.33 | -$8.37 | -$0.02 | $0.14 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $447.9M | $439.2M | $453.8M | $467.8M | $352.4M | |
| Total Assets | $1.6B | $1.8B | $1.7B | $1.7B | $1.1B | |
| Current Liabilities | $154.6M | $152.9M | $158.5M | $205.2M | $137.2M | |
| Total Liabilities | $396.2M | $510M | $436.2M | $433.4M | $268.4M | |
| Total Equity | $1.3B | $1.3B | $1.3B | $1.2B | $839.4M | |
| Total Debt | $175M | $254.4M | $210.9M | $176.6M | $107.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $82.3M | $31.2M | $134.4M | -$8M | $25.7M | |
| Cash From Investing | -$17.7M | $23.6M | -$34.6M | -$2M | -$9.1M | |
| Cash From Financing | -$71.1M | -$72.8M | -$77.5M | -$700K | -$29.1M | |
| Free Cash Flow | $64M | $13.3M | $114M | -$12.1M | $19M | |
AVNS
Sector
Market Cap
$559.6M
$33.4M
Price % of 52-Week High
47.71%
46.84%
Dividend Yield
0%
0%
Shareholder Yield
2.72%
-0.6%
1-Year Price Total Return
-38.3%
-37.4%
Beta (5-Year)
1.141
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$12.45
200-day SMA
Sell
Level
$17.26
Bollinger Bands (100)
Sell
Level
12.39 - 15.75
Chaikin Money Flow
Buy
Level
14.5M
20-day SMA
Sell
Level
$12.56
Relative Strength Index (RSI14)
Sell
Level
43.06
ADX Line
Sell
Level
11.32
Williams %R
Buy
Level
-82.4561
50-day SMA
Sell
Level
$12.58
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
11.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.2046)
Sell
CA Score
(Annual)
Level (-0.4798)
Buy
Beneish M-Score
(Annual)
Level (-4.5249)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.2659)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
Stock Forecast FAQ
In the current month, AVNS has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The AVNS average analyst price target in the past 3 months is $14.00.
-
Where Will Avanos Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avanos Medical share price will rise to $14.00 per share over the next 12 months.
-
What Do Analysts Say About Avanos Medical?
Analysts are divided on their view about Avanos Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avanos Medical is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Avanos Medical's Price Target?
The price target for Avanos Medical over the next 1-year time period is forecast to be $14.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is AVNS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avanos Medical is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of AVNS?
You can purchase shares of Avanos Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avanos Medical shares.
-
What Is The Avanos Medical Share Price Today?
Avanos Medical was last trading at $12.10 per share. This represents the most recent stock quote for Avanos Medical. Yesterday, Avanos Medical closed at $12.10 per share.
-
How To Buy Avanos Medical Stock Online?
In order to purchase Avanos Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Gamestop’s Bitcoin Strategy Going To Succeed?
When GameStop (NYSE: GME) announced in Q1 that its board had…
How High Will Roku Stock Go?
Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
